DUBLIN – Funding continues to flow to European biotech, with Cardio3 Biosciences SA and Quantum Genomics SA raising €32 million (US$36 million) and €12.9 million (US$14.44 million), respectively, in secondary offerings last week. Both transactions confirm the current appetite among investors for European biotech, but a much sterner test of that support is on the near-term horizon, as a new Irish-American firm Malin Corp. plc unveiled ambitious plans to raise €275 million to €325 million in an IPO in Dublin shortly.